The chief investigators of the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial have released a statement reporting that dexamethasone may reduce mortality in hospitalized COVID-19 patients.

The RECOVERY trial is a randomized controlled trial of multiple treatments for patients admitted to the hospital with COVID-19. Over 11,500 patients have been randomized to the following treatment arms or to no additional treatment:

  • Lopinavir-ritonavir

  • Low-dose dexamethasone

  • Hydroxychloroquine (this arm was halted due to lack of efficacy)

  • Azithromycin

  • Tocilizumab

  • Convalescent plasma

Investigators reported that treatment with dexamethasone reduced the 28-day mortality rate by 17%, with a highly significant trend showing greatest benefit among those patients requiring ventilation. Investigators found no evidence of benefit for patients who did not require oxygen; non-hospitalized patients were not included in this study.

These results are not yet published in a peer-reviewed journal.

University of Oxford. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19 [news release]. June 16, 2020. Available at: click here. Accessed June 17, 2020.